Department of Emergency Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.
Department of Research, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.
BMC Emerg Med. 2021 Aug 28;21(1):97. doi: 10.1186/s12873-021-00491-7.
During the COVID-19 outbreak, healthcare providers might have avoided droplet/aerosol-generating procedures, such as non-invasive ventilation (NIV) and high-flow nasal cannula (HFNC) due to the concern of themselves being infected. We hypothesized that this change of practice could have also occurred to other non-COVID-infected patients in the Emergency Department (ED).
A retrospective analytic study was conducted in the ED of Siriraj Hospital, Bangkok, Thailand, including adult patients presenting with signs and symptoms of respiratory distress between 1 March and 30 April 2020 (the COVID period). A comparison group using the same inclusion criteria was retrieved from 1 March to 30 April 2019 (the pre-COVID period). The primary outcome was rate of NIV and HFNC use. The secondary outcomes were rate of intubation, failure of NIV and HFNC, complications, and mortality.
A total of 360 and 333 patients were included during the pre-COVID and COVID periods, respectively. After adjusting for baseline differences, patients in the COVID period were less likely to receive either NIV or HFNC than the pre-COVID period (adjusted OR 0.52 [95%CI 0.29-0.92]). Overall, intubation rate was similar between the two study periods. However, patients in respiratory distress with pulmonary edema had a relatively higher intubation rate in the COVID period. There were higher failure rates of NIV and HFNC, more infectious complications, and a higher rate of mortality in the pre-COVID period.
During the COVID-19 pandemic, the overall usage of NIV and HFNC in emergency non-COVID patients decreased. Although not affecting the overall intubation rate, this change of practice could have affected some groups of patients. Therefore, treatment decisions based on a balance between the benefits to the patients and the safety of healthcare providers should be made.
在 COVID-19 疫情期间,医护人员可能由于担心自身感染而避免进行飞沫/气溶胶产生的程序,例如无创通气(NIV)和高流量鼻导管(HFNC)。我们假设这种做法的改变也可能发生在急诊科(ED)的其他非 COVID 感染患者中。
这项在泰国曼谷 Siriraj 医院 ED 进行的回顾性分析研究纳入了 2020 年 3 月 1 日至 4 月 30 日(COVID 期间)出现呼吸窘迫症状和体征的成年患者。通过相同的纳入标准,从 2019 年 3 月 1 日至 4 月 30 日(COVID 前期间)检索到一个对照组。主要结局是 NIV 和 HFNC 的使用率。次要结局是插管率、NIV 和 HFNC 失败率、并发症和死亡率。
COVID 前期间和 COVID 期间分别纳入了 360 例和 333 例患者。调整基线差异后,COVID 期间患者接受 NIV 或 HFNC 的可能性低于 COVID 前期间(校正 OR 0.52 [95%CI 0.29-0.92])。总体而言,两个研究期间的插管率相似。然而,COVID 期间患有肺水肿的呼吸窘迫患者的插管率相对较高。COVID 前期间 NIV 和 HFNC 的失败率较高,感染性并发症较多,死亡率较高。
在 COVID-19 大流行期间,急诊非 COVID 患者中 NIV 和 HFNC 的总体使用率下降。尽管这一做法的改变并未影响总体插管率,但可能影响了某些患者群体。因此,应根据患者获益与医护人员安全之间的平衡做出治疗决策。